Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

NCT00061672 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Hodgkin's Lymphoma

Interventions

DRUG: ABT-510 - Thrombospondin-1 Mimetic

Sponsor

Abbott